Back to journals
Academic Journal

Journal of Neurochemistry

4 Papers Indexed in Blossom

Data updated

Research Footprint

Journal of Neurochemistry has 4 tracked papers indexed in Blossom (2021–2024) from 30 authors, most often covering MDMA, Psilocybin and 5-MeO-DMT, across PTSD, Depressive Disorders and Immunology & Inflammation.

Published Papers

Open Accessindividual

Bioisosteric analogs of MDMA: Improving the pharmacological profile?

The authors synthesised and characterised three methylenedioxy bioisosteres of MDMA (ODMA, TDMA and SeDMA) that retain activity at human serotonin, dopamine and norepinephrine transporters but show reduced agonism at 5‑HT2A/2B/2C receptors, altered hepatic metabolism (no phase II metabolites, N‑demethylation conserved) and weaker interactions with hOCTs and hPMAT. These pharmacological and metabolic differences suggest they could be promising lower‑risk therapeutic alternatives to MDMA, warranting further preclinical and clinical evaluation.

Published
Journal
Journal of Neurochemistry
Authors
Sofia, A., Hemmer, S., Bock, H. A., Alves Da Silva, L., Scott, K. R., Kastner, N., Bhatt, M., Niello, M., Jäntsch, K., Kudlacek, |. O., Bossi, E., Stockner, T., Meyer, M. R., Mccorvy, J. D., Brandt, S. D., Kavanagh, P., Sitte, H. H., Kudlacek, O.
Open Accessmeta

The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)

This review (2022) explores the current state of research surrounding 5-MeO-DMT. The authors provide food for thought on its therapeutic potential as well as the commercialization of the substance.

Published
Journal
Journal of Neurochemistry
Authors
Reckweg, J., Uthaug, M. V., Szabo, A., Davis, A. K., Lancelotta, R., Mason, N. L., Ramaekers, J. G.
Open Accessindividual

Psychedelic-Inspired Approaches for Treating Neurodegenerative Disorders

The authors propose that psychedelic‑inspired treatments, acting primarily via the 5‑HT2A receptor to enhance neurotrophic signalling, neuronal growth and immune modulation, could rescue cortical atrophy common to neurodegenerative diseases. They further suggest these compounds may help treat behavioural and psychological symptoms of dementia and warrant targeted preclinical and clinical investigation.

Published
Journal
Journal of Neurochemistry
Authors
Olson, D. E.
Open Accessmeta

From Psychiatry to Neurology: Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders

This review evaluates preclinical and early clinical evidence that psychedelic tryptamines, particularly psilocybin, could be repurposed from psychiatry to neurology as prospective therapeutics for brain injury and neurodegenerative disorders. It highlights findings that psychedelics promote neuroplasticity, synaptogenesis and neural progenitor proliferation and reduce pro‑inflammatory cytokines (e.g. IL‑1β, IL‑6, TNF‑α), while emphasising that the precise molecular mechanisms and neural–glial interactions remain to be determined.

Published
Journal
Journal of Neurochemistry
Authors
Nichols, C. D., Wiatr, K., Figiel, M., Kozłowska, U.

Quick Facts

Papers Indexed
4
h-Index
267
Open Access
No
Publisher
Wiley
Country
United Kingdom
Website
Visit